Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
Lumos Pharma announced that new analyses from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials will be presented at the 2024 Annual Meeting of the Endocrine Society (ENDO) in Boston from June 1-4, 2024.
The two posters cover significant findings in pediatric growth hormone deficiency treatments. The first, presented by Dr. Fernando Cassorla, focuses on oral LUM-201 and its ability to restore growth hormone secretion in children. The second, by Dr. Adam Stevens, examines how growth responses to LUM-201 depend on the pattern of hormone secretion.
- Acceptance of Phase 2 trial data for presentation at a major conference validates the significance of Lumos Pharma's research.
- New analyses indicate that oral LUM-201 can restore growth hormone secretion in children with growth hormone deficiency.
- The data show that growth responses to LUM-201 vary based on hormone secretion patterns, providing valuable insights for personalized treatment approaches.
- The announcement focuses on Phase 2 trial data, indicating that LUM-201 is still in early clinical stages and not yet close to market approval.
- There is no mention of financial improvements or immediate revenue opportunities arising from these findings.
- Continued dependence on successful future trials and regulatory approvals poses inherent risks for investors.
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), to be held in Boston, MA June 1-4, 2024.
Poster Session P069 – Monday June 3, 12:00-1:30 PM ET
- Poster MON-111 : Oral LUM-201 Restores Pulsatile Growth Hormone Secretion and Growth Response in Moderate Pediatric Growth Hormone Deficiency (PGHD): Key Discoveries from Phase 2 of OraGrowtH212 Trial (Fernando Cassorla, MD, Chief of Pediatric Endocrinology, University of Chile, et al)
Late-Breaking Poster Session P108 – Monday June 3, 12:00-1:30PM ET
- Poster MON-704: Growth Response to Oral Growth Hormone Secretagogue LUM-201 in Children with Moderate GH Deficiency (GHD) is dependent on the Pattern of Pulsatile GH Secretion Stimulated by LUM-201 (Adam Stevens, MSc, PhD, Lecturer, University of Manchester, et al)
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
What are the dates for Lumos Pharma's presentations at ENDO 2024?
What is the focus of Lumos Pharma's poster MON-111 at ENDO 2024?
What does Lumos Pharma's poster MON-704 at ENDO 2024 analyze?
What is the stock symbol for Lumos Pharma?
Where will the ENDO 2024 conference be held?
